Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Tavapadon Clinical vs Commercial Tablets
NCT06895356Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tavapadon in Parkinson's disease (PD) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Adverse Events, Maximum Observed Plasma Concentration (Cmax) of Tavapadon and 6 more. Started Mar 2025; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06895356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895356.